BIIB Stock — Biogen Inc.

Biogen Inc. (BIIB)

Updated October 16, 2026.

BIIB is a Stock. Total return is 7344.8% over the past 35.1 years.

Biogen is a biotechnology company that discovers, develops, manufactures, and sells therapies for neurological, immunological, and psychiatric conditions. Its marketed products include treatments for multiple sclerosis, spinal muscular atrophy, Alzheimer's disease, various cancers, and other serious diseases, along with biosimilar versions of established biologics. The company does not currently have an established dividend distribution program.

BIIB performance

Price and return data through 2026-10-16.

Total return is 7344.8% over the past 35.1 years. Over the past year its total return — price change plus distributions reinvested — is 63.5%. Its deepest 1-year drawdown was 14.3%.

BIIB key facts

Asset type

Stock

Asset class

Equity

Inception date

09/17/1991

Distribution frequency

None

Last close

$232.65 (as of 2026-10-16)

Market cap

$34,374,967,635

Average volume

1462552.0

Beta

0.092

Payout ratio

0.0%

P/E ratio

41.32

Forward P/E

13.947

EPS

$5.63

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BIIB risks and drawbacks

The deepest 1-year drawdown on record here is 14.3%.

Who may consider BIIB — and who may not

It is a weaker fit for investors who need monthly cash flow (BIIB does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on BIIB

• ETFs holding BIIB
• All tickers starting with B

Tagged: Pharmaceutical.

Frequently asked questions